Current Takeaway
Both ME/CFS and post-COVID condition show objective signs of peripheral small-fiber neuropathy (SFN) and autonomic dysfunction that are measurable with standard neurological tools. A comparative study using tilt-table testing, Sudoscan, and heat-evoked nerve potentials found elevated resting heart rates, a high prevalence of POTS, and delayed C-fiber responses to heat stimuli in both patient groups compared with healthy controls. Notably, abnormal sweat-gland function appeared more frequently in the hands than the feet — a non-length-dependent pattern that differs from the distal-to-proximal neuropathy typical of diabetes or chemotherapy, and that may point toward an immune-mediated or dysautonomic mechanism rather than a metabolic one.
A parallel line of mechanistic evidence proposes mast cell activation as a plausible driver linking SARS-CoV-2 exposure to ongoing peripheral nerve damage. Spike-protein-activated mast cells, which sit in close anatomical proximity to peripheral nerves and blood vessels, release neurotoxic mediators including tryptase and interleukin-6 that can sensitise small-calibre sensory fibres and disrupt both local and central vascular barriers. The source coverage is small — one cross-sectional study and one narrative review — so these mechanistic links remain plausible but not established, and no clinical recommendations can be drawn from the current evidence.
Why This Matters
Neuropathic symptoms — burning pain, altered temperature sensation, patchy skin sensations, and autonomic dysregulation — are among the most disabling and least acknowledged features of ME/CFS and post-COVID. For carers and patients, the central difficulty is that these symptoms are frequently dismissed because standard nerve conduction studies, which test large myelinated fibres, return normal results. Small unmyelinated C-fibres and thinly myelinated Aδ-fibres require different testing — Sudoscan, quantitative sensory testing, heat-evoked potentials, skin punch biopsy for intraepidermal nerve fibre density, or corneal confocal microscopy — and those tools are rarely available outside specialist neurology centres.
The research collected here establishes that objective SFN findings are present in a meaningful proportion of ME/CFS and post-COVID patients and that the neuropathy has distinctive features, particularly the non-length-dependent distribution, that may help distinguish it from other causes. A mechanistic framework centred on mast cell activation offers a biological explanation for why these symptoms persist long after acute infection resolves. Understanding the mechanism matters because it points toward a specific class of therapeutic targets — mast cell stabilisers, antihistamines, and anti-inflammatory interventions — even though clinical validation of those targets is still at an early stage.
State of Evidence
- Established: Standard large-fibre nerve conduction studies are insufficient to detect SFN; objective SFN assessment requires Sudoscan, heat- or cold-evoked potentials, skin punch biopsy, or corneal confocal microscopy. Elevated resting heart rate and a high prevalence of POTS (31% in ME/CFS, 14% in post-COVID in the Azcue et al. cohort) are demonstrable with standard tilt-table testing.
- Plausible but early: A non-length-dependent SFN — abnormal sweat-gland function in the hands more than the feet — is present in a subset of ME/CFS and post-COVID patients and may reflect an immune-mediated mechanism rather than a metabolic or length-dependent axonal one. Mast cell activation triggered by spike-protein binding to ACE2 and TLR4 receptors is a biologically coherent mechanism for peripheral nerve sensitisation, autonomic disruption, and blood-brain-barrier compromise in Long COVID.
- Not established: Whether SFN prevalence and severity differ meaningfully between ME/CFS and post-COVID beyond the point estimates in a single heterogeneous cohort. Whether mast-cell-directed treatments alter objective SFN measures or autonomic parameters in controlled trials. Whether corneal confocal microscopy — recommended by the Azcue authors as a next step — provides additional diagnostic signal beyond Sudoscan and evoked potentials in these populations.
- Key limitations: The Azcue et al. study used unequal group sizes (87 post-COVID, 50 ME/CFS, 50 controls) and unequal sex distributions that could introduce bias; a relatively high rate of pathological autonomic findings in controls may have narrowed between-group differences. The Morcos & Theoharides review is a narrative synthesis of preclinical models and case reports without systematic search methods or meta-analysis; the mast cell hypothesis is mechanistically coherent but not confirmed in controlled clinical trials. There are no skin-punch biopsy data from either source. The total primary source count is two, making this an early, provisional thread.
Timeline
2023-11-15 - Cross-sectional study documents SFN and POTS in ME/CFS and post-COVID using Sudoscan and evoked potentials
Azcue et al. published a comparative study in the Journal of Translational Medicine recruiting 87 patients with post-COVID condition, 50 with ME/CFS, and 50 healthy controls at centres in the Basque Country, Spain. Autonomic function was assessed with tilt-table testing, the Valsalva manoeuvre, and deep-breathing tests; small-fiber function was evaluated with Sudoscan (sweat gland electrochemical conductance as a surrogate for C-fibre innervation density) and with heat- and cold-evoked nerve potential latencies. Both patient groups showed significantly elevated resting and standing heart rates relative to controls, with POTS criteria met by 31% of ME/CFS and 13.8% of post-COVID participants. Both groups also showed significantly delayed responses to heat stimuli, indicating damage to unmyelinated C-type sensory fibres. The key structural finding was that Sudoscan abnormalities clustered in the hands more than the feet — a non-length-dependent distribution suggesting patchy, possibly immune-mediated nerve loss rather than the distal-to-proximal dying-back pattern seen in toxic or metabolic neuropathies. The study was the first to directly compare these neurological and autonomic parameters across both patient groups in the same protocol. The authors called for replication with larger, better-matched control groups and suggested adding corneal confocal microscopy and autoantibody profiling to future assessments to investigate autoimmune drivers.
Sources:
2026-03-06 - Narrative review frames mast cell activation as a unifying mechanism for Long COVID neuropathy
Morcos and Theoharides published a narrative review in the Journal of Neuropathology & Experimental Neurology examining mast cells as the primary mechanism connecting SARS-CoV-2 exposure to persistent neuropathic pain and autonomic dysfunction in Long COVID. Mast cells are positioned in close anatomical proximity to peripheral nerves and vascular walls throughout the body; the review synthesises preclinical models and clinical case reports showing that the SARS-CoV-2 spike protein can bind to mast cell surface receptors including ACE2 and TLR4, triggering degranulation and the release of tryptase, interleukin-6, and other pro-inflammatory mediators. Tryptase directly sensitises peripheral nociceptors (including small-calibre Aδ and C fibres) and can degrade the extracellular matrix near nerve endings; interleukin-6 amplifies systemic inflammation and contributes to blood-brain-barrier disruption. The authors note that this pathological pattern closely mirrors what is found in skin-biopsy-confirmed SFN, and that clinical observations of symptom improvement with mast cell stabilisers and antihistamines are consistent with the proposed mechanism — though no controlled trial data are cited. Because the review is a narrative synthesis without systematic methods, it should be read as a mechanistic framework rather than evidence of treatment efficacy. The biological rationale is coherent and links well to the non-length-dependent SFN signal found in the Azcue cohort, but the mast-cell mechanism remains unvalidated in ME/CFS-specific controlled studies.
Sources:
Open Questions
- Whether skin punch biopsy — the gold-standard method for quantifying intraepidermal nerve fibre density — would confirm and extend the Sudoscan-based SFN findings in ME/CFS and post-COVID cohorts.
- Whether corneal confocal microscopy, which is non-invasive and measures corneal nerve fibre length and density as a proxy for systemic small-fiber status, provides independent diagnostic signal in these populations, as the Azcue authors recommended.
- Whether the non-length-dependent distribution of SFN abnormalities distinguishes an immune-mediated or dysautonomic subgroup from patients whose neuropathy follows a more conventional length-dependent pattern.
- Whether mast-cell-directed interventions — stabilisers, H1/H2 antihistamines, or anti-IL-6 approaches — produce measurable changes in objective SFN or autonomic parameters when tested in controlled trials with ME/CFS or Long COVID patients.
- Whether autoantibodies (e.g., against autonomic receptors) explain part of the neuropathic burden, as proposed by the Azcue group, and whether their presence correlates with SFN severity or POTS status.